Posted by Michael Wonder on 02 Apr 2019
Novartis first-in-class Cosentyx approved in China for psoriasis patients
2 April 2019 - China Health Authority NMPA approved Cosentyx (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the China Health Authority NMPA approved Cosentyx (secukinumab), the first-in-class interleukin-17A inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
A Phase III study in patients in China with psoriasis confirmed a sustained safety profile and rapid onset of relief with Cosentyx as early as week 3. Data showed close to 9/10 patients who received Cosentyx (300 mg on an every 4 week dosing regimen after loading) achieved clear or almost clear skin after 16 weeks.
